Drug Trial Radar · NCT05133804
Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
Jun 1, 2022
Primary completion
Oct 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- University of HaifaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.
Conditions
- Posttraumatic Stress Disorder
Interventions
MethylphenidateDrug
Ritalin 10mg
ReboxetineDrug
Reboxetine 4mg
PlaceboDrug
Placebo matched to Reboxetine
PlaceboDrug
Placebo matched to Ritalin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual (DSM)-5 (CAPS-5) between baseline score (before treatment) and score on day 26 (after treatment)Time frame: Day 1 and day 26
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Emek Medical Center
Afula, Israel · Recruiting
University of Haifa
Haifa, Israel · Recruiting
Lev HaSharon Mental Health Center
Netanya, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.